From Precision Therapies to Imprecise Patient Selection: Are We Ready for Biologics in COPD?

Juan Marco Figueira-Gonçalves, Rafael Golpe, Javier de Miguel-Díez · 2026

Read From Precision Therapies to Imprecise Patient Selection: Are We Ready for Biologics in COPD? by Juan Marco Figueira-Gonçalves, Rafael Golpe, Javier de Miguel-Díez (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634060.txt.

Description

Juan Marco Figueira-Goncalves and co-authors question whether patient selection is ready for biologic drugs in COPD. Biologics mark a shift in preventing flare-ups of this lung disease. After decades of slow progress, targeted drugs now exist.

Selection today rests on two rough clinical proxies. One is blood eosinophil counts as a sign of one inflammation type. The other is flare-ups that persist despite full inhaled therapy. The authors argue these proxies miss much disease variety. Precise drugs arrived before precise selection, they say. When inhaled therapy counts as fully optimized is also unclear. The piece urges better markers before wide biologic use. It frames a key debate for lung specialists.

Catalog record

CREATORJuan Marco Figueira-Gonçalves, Rafael Golpe, Javier de Miguel-Díez
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13634060

Browse the full library · About the Tower of Babel